REFERENCES
- Lau YL, Chan LC, Chan YY, Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong – implications for population screening. N Engl J Med. 1997; 336(18):1298–1301.
- Borgna-Pignatti C, Cappellini MD, De Stefano P, Survival and complications in thalassemia. Ann NY Acad Sci. 2005; 1054:40–47.
- Ha SY, Chik KW, Ling SC, A randomized controlled study evaluating the safety and efficacy of deferiprone treatment in thalassemia major patients from Hong Kong. Hemoglobin. 2006; 30(2):263–274.
- Pennell DJ. T2* magnetic resonance and myocardial iron in thalassemia. Ann NY Acad Sci. 2005; 1054:373–378.
- Lam WW, Au WY, Chu WC, One-stop measurement of iron deposition in the anterior pituitary, liver, and heart in thalassemia patients. J Magn Reson Imaging. 2008; 28(1):29–33.
- Olivieri NF, Nathan DG, MacMillan JH, Survival in medically treated patients with homozygous β-thalassemia. N Engl J Med. 1994; 331(9):574–578.
- Porcu M, Landis N, Salis S, Effects of combined deferiprone and desferrioxamine iron chelating therapy in β-thalassaemia major end-stage heart failure: a case report. Eur J Heart Fail. 2007; 9(3):320–322.
- Tanner MA, Galanello R, Dessi C, A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007; 115(14):1876–1884.
- Tanner MA, Galanello R, Dessi C, Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. J Cardiovasc Magn Reson. 2008; 10(1):12.
- Christoforidis A, Haritandi A, Tsatra I, Four-year evaluation of myocardial and liver iron assessed prospectively with serial MRI scans in young patients with β-thalassaemia major: comparison between different chelation regimens. Eur J Haematol. 2007; 78(1):52–57.